PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.

Inclusion Criteria:

• Patients with age ≥ 18 years
• diagnosis of lung cancer,head and neck cancer,colorectal cancer,ovarian cancer
• Karnofsky Performance Status ≥ 70
• life expectancy of at least 3 months
• Written informed consent are acquired

Exclusion Criteria:

• uncontrolled infection,Temperature is 38.0 ℃ or higher
• pregnancy
• Other situations that investigators consider as contra-indication for this study